“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Incannex Healthcare
Incannex Healthcare is an Australian dual-listed biotech company focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. These therapies are being designed to target indications with unmet need, including obstructive sleep apnea, generalized anxiety disorder, trauma and inflammatory conditions.
Incannex Healthcare — 1 video in collection
Incannex Healthcare (Nasdaq: IXHL, ASX: IHL) is an Australian biotech specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies.
Incannex has 28 clinical programmes in progress and holds one of the world’s largest portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes.
The company’s most advanced clinical asset, IHL-42X, is being developed for the treatment of obstructive sleep apnoea and will see bioavailability and bioequivalence studies roll out in 2023.
Watch Dr Mark Bleackley, Incannex’s chief scientific officer, and Joel Latham, the company’s MD and CEO, being interviewed by Vivienne Parry, to find out more about IHL-42X and Incannex Healthcare’s investment case.
Get access to the very latest content matched to your personal investment style.
